Neoadjuvant PD-L1 Plus CTLA-4 Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neoadjuvant PD-L1 Plus CTLA-4 Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
Nat. Med. 2020 Oct 12;[EPub Ahead of Print], J Gao, N Navai, O Alhalabi, A Siefker-Radtke, MT Campbell, RS Tidwell, CC Guo, AM Kamat, SF Matin, JC Araujo, AY Shah, P Msaouel, P Corn, J Wang, JN Papadopoulos, SS Yadav, JM Blando, F Duan, S Basu, W Liu, Y Shen, Y Zhang, MD Macaluso, Y Wang, J Chen, J Zhang, A Futreal, C Dinney, JP Allison, S Goswami, P SharmaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.